Navigation Links
Trubion Announces Dates for Second-Quarter and First-Half 2010 Earnings Conference Call
Date:8/13/2010

SEATTLE, Aug. 13 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: http://photos.prnewswire.com/prnh/20090320/TRUBIONLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com.

Second-Quarter and First Six Months 2010 Conference Call: 2 p.m. PDT/5 p.m. EDT, Aug. 16, 2010

Trubion will host a conference call and webcast to discuss its second quarter and six months ended 2010 financial results and provide an update on business activities. The call will be held Aug. 16 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's website at http://investors.trubion.com, or by calling (877) 564-1186 or (973) 409-9686. A replay of the discussion will be available beginning 8 p.m. Eastern Time from Trubion's website or by calling (800) 642-1687 or (706) 645-9291 and entering 93177343. The telephone replay will be available until midnight, Aug. 30, 2010.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the Company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules as well as simultaneously neutralizing soluble ligands. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

TRBN-G

Contact:

Jim DeNike

Senior Director, Corporate and Marketing Communications

Trubion Pharmaceuticals, Inc.

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com



Waggener Edstrom Worldwide Healthcare

Jenny Moede

Executive Vice President

(503) 443-7507

jmoede@waggeneredstrom.com




'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
7. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
8. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
9. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
10. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
11. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  "Blood Tests ... cancers announced ....." The Diagnostic, Monitoring and ... in cancer diagnostics is occurring using in vitro ... new company with impressive backing, has announced a ... technology is moving faster than the market. New ...
(Date:12/6/2016)... 6, 2016 The pen needles market is ... USD 1.65 billion in 2016, growing at a CAGR ... 2021. Over the years, the pen needles market ... to the growing demand for safety injections in the ... of safety pen needles with an aim to reduce ...
(Date:12/6/2016)... Dec. 6, 2016  BTL Aesthetics today announced ... its BTL Vanquish ME device was effectively redesigned ... to the targeted tissue. The result: Significantly better ... with BTL Vanquish ME versus BTL Vanquish. ... network and their patients with the most highly-advanced ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... “Fred Rides a Train” allows readers to tag along ... “Fred Rides a Train” is the creation of published author, Janet Morrison, who has ... in Michigan. The "Fred, the Dog" series is her first attempt at writing for ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Business ... Summit in Reston, VA on March 21-22, 2017. This premier event features business ... experiences from a cross-section of industries such as financial services, insurance, healthcare, manufacturing, ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... NuevaCare, ... Francisco Peninsula region, is proud to announce new city-specific pages as part of its ... for the elderly, they often look, first, for local agencies serving their city. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... People with Parkinson’s disease and ... a type of MRI, according to a study appearing online in the journal ... system characterized by tremors or trembling and stiffness in the limbs, impaired balance ...
(Date:12/6/2016)... Los Angeles, CA (PRWEB) , ... December 06, ... ... to suffer from erectile dysfunction because of a higher risk of serious health ... article on Star2.com. Dr. Peiman Soleymani of Beverly Hills Periodontics & ...
Breaking Medicine News(10 mins):